Surbhi Sidana is a Hematology physician affiliated with Palo Alto University. OpenAlex indexes 417 publications with 7,751 citations (h-index 40); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 16 Apr 2024.
Clinical trials
- Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Sponsor: Stanford University
- Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
Sponsor: Stanford University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20255 payments$23,500openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202515 payments$11,455openpaymentsdata.cms.gov ↗
- Janssen Global Services, LLCProgram year202517 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine
2025 - Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
2025 - Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Tait Shanafelt, MD
Palo Alto University
Victor Froelicher, MD
Palo Alto University
Michael Marmor, MD
Palo Alto University
Ronald Dalman, MD
Palo Alto University
Joseph Antin, MD
Boston University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”